Wrap Text
ASPI Isotopes’ UK Subsidiary, Quantum Leap Energy Ltd., enters early engagement process with UK Nuclear Regulators
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
ASPI Isotopes' UK Subsidiary, Quantum Leap Energy Ltd., enters early engagement process
with UK Nuclear Regulators
Rich Deakin joins QLE Ltd as Senior Vice President and Managing Director UK Strategic
Projects, bringing significant nuclear industry experience.
Washington, D.C., November 5, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI)
("ASP Isotopes" or the "Company"), an advanced materials company focused on developing
technologies and processes for the production of isotopes for multiple industries, today announced a
regulatory progress update in its initiative to produce High-Assay Low Enriched Uranium ("HALEU") in
the United Kingdom. The Company's UK subsidiary, Quantum Leap Energy Ltd ("QLE Ltd"), has
formally commenced early engagement for regulatory pathways ("Early Engagement") with the UK's
regulators on new nuclear projects.
Following successful completion of national security due diligence, the Department for Energy Security
and Net Zero ("DESNZ") confirmed QLE Ltd's eligibility to enter Early Engagement with the Office for
Nuclear Regulation ("ONR"), the regulator for the nuclear industry in the United Kingdom. HALEU is
required to fuel most advanced modular reactor designs and this development sets ASP Isotopes'
subsidiary, Quantum Leap Energy, on the path to be the first commercial producer of HALEU in the UK.
Bill Eden, President of QLE Ltd, commented:
"By producing the HALEU required to fuel the next generation of advanced modular reactors, QLE Ltd
will contribute directly to the UK's clean power, energy security, and economic growth agendas. Our
early engagement with ONR is a vital step in establishing the safety, security, and safeguarding
standards that will underpin our responsible uranium enrichment in the UK."
Next steps include continued engagement with the ONR and environmental regulators while QLE Ltd
selects an optimal site for its UK operations. The company is also preparing its nuclear site licence and
environmental permit applications and will work closely with DESNZ to obtain permission to enrich
uranium for civil and commercial purposes. While definitive regulatory timelines have not yet been
confirmed, internal estimates indicate a potential pathway to full licensing is achievable within this
decade, subject to regulatory and site-specific progress.
In addition, Rich Deakin joined QLE Ltd this week as Senior Vice President and Managing Director, UK
Strategic Projects. Rich brings more than 35 years of experience across civil and defence nuclear
sectors in the USA, UK, and Japan. He has previously held senior roles at Rolls-Royce, NuScale Power,
Sellafield Ltd, and most recently directed UK Research and Innovation's Low-Cost Nuclear Challenge.
He is also a director and trustee of the Nuclear Institute.
Rich Deakin, Senior Vice President and Managing Director UK Strategic Projects, commented:
"I am delighted to be joining QLE Ltd at this pivotal moment for both the company and the wider UK
nuclear industry. Establishing a sovereign HALEU production capability is a strategic national objective,
and QLE Ltd's mission aligns perfectly with the UK's ambition to deliver clean, secure, and competitive
energy. I look forward to helping build the partnerships and technical capability that will enable QLE Ltd
to play a leading role in the global HALEU supply chain."
This initiative further reinforces ASP Isotopes' global strategy to expand its enrichment capabilities
across multiple regions and applications - from advanced nuclear fuels to next-generation materials -
supporting the transition to cleaner and more secure energy systems worldwide.
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development
of technology and processes to produce isotopes for use in multiple industries. The Company employs
proprietary technology, the Aerodynamic Separation Process ("ASP technology"). The Company's initial
focus is on producing and commercializing highly enriched isotopes for the healthcare and technology
industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum
Enrichment technology that the Company is developing. The Company has isotope enrichment facilities
in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass
(light isotopes).
There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and
Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging
healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy
applications. We believe the ASP technology (Aerodynamic Separation Process) is ideal for enriching
low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are
neither historical facts nor assurances of future performance. Instead, they are based only on our
current beliefs, expectations, and assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the economy, and other future conditions.
Forward-looking statements can be identified by words such as "believes," "plans," "anticipates,"
"expects," "estimates," "projects," "will," "may," "might," and words of a similar nature. Examples of
forward-looking statements include, among others but are not limited to, the anticipated receipt of
regulatory approvals for enrichment of uranium, the commencement of supply of isotopes to customers,
the construction of additional enrichment facilities, and statements we make regarding expected
operating results, such as future revenues and prospects from the potential commercialization of
isotopes, future performance under contracts, and our strategies for product development, engaging
with potential customers, market position, and financial results. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that
are difficult to predict, many of which are outside our control. Our actual results, financial condition, and
events may differ materially from those indicated in the forward-looking statements based upon a
number of factors. Forward-looking statements are not a guarantee of future performance or
developments. You are strongly cautioned that reliance on any forward-looking statements involves
known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-
looking statements. There are many important factors that could cause our actual results and financial
condition to differ materially from those indicated in the forward-looking statements, including, but not
limited to: the failure to obtain necessary regulatory approvals for the proposed acquisition of Renergen;
disruption from the proposed acquisition of Renergen making it more difficult to maintain business and
operational relationships; significant transaction costs and unknown liabilities related to the proposed
acquisition of Renergen; litigation or regulatory actions related to the proposed acquisition of Renergen;
the outcomes of various strategies and projects undertaken by the Company; the potential impact of
laws or government regulations or policies in South Africa, the United Kingdom or elsewhere; our
reliance on the efforts of third parties; our future capital requirements and sources and uses of cash;
our ability to obtain funding for our operations and future growth; our reliance on the efforts of third
parties; our ability to complete the construction and commissioning of our enrichment plants or to
commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to
obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any
current and future commercial arrangements; our ability to complete certain transactions and realize
anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights,
certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part
I, Item 1A. "Risk Factors" of the company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2024 and any amendments thereto and in the company's subsequent reports and filings
with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this
press release is based only on information currently available to us and speaks only as of the date on
which it is made. We undertake no obligation to publicly update any forward-looking statement, whether
as a result of new information, future developments or otherwise. No information in this press release
should be interpreted as an indication of future success, revenues, results of operation, or stock price.
All forward-looking statements herein are qualified by reference to the cautionary statements set forth
herein and should not be relied upon.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
5 November 2025
Sponsor
Valeo Capital Proprietary Limited
Date: 05-11-2025 03:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
